NO
NORD.US Nordicus Partners Corporation Common Stock
- Market cap
- USD 48.8M
- P/E
- -
- P/B
- 0.79x
- ROE
- -6.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Aug 2026.
Is NORD.US undervalued?
Graham numberThe Graham number of Nordicus Partners Corporation Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nordicus Partners Corporation Common Stock fundamental analysis
No fundamental analysis for Nordicus Partners Corporation Common Stock yet.
Nordicus Partners Corporation Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nordicus Partners Corporation Common Stock
Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California.
Full company profileNordicus Partners Corporation Common Stock financial statements
Nordicus Partners Corporation Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 274M | 324M | 475M | 577M | 856M | 0.00 | 0.00 | 2.50K | 5.00K | 0.00 |
| Gross Profit | 148M | 176M | 260M | 255M | 380M | - | - | - | - | - |
| Operating Income | 49.3M | 62.3M | 88.1M | 78.7M | 121M | -309K | -8.48M | -308K | -2.92M | -4.37M |
| EBITDA | - | - | - | - | - | - | -8.47M | -298K | -2.91M | -4.04M |
| Net Income | - | -23.0M | -90.2M | 7.40M | 47.1M | -287K | -8.47M | -298K | -2.90M | -4.00M |
| EPS | - | - | - | - | - | -0.27 | -7.85 | -0.27 | -0.17 | -0.21 |
| Balance Sheet | ||||||||||
| Total Assets | 667M | 1.13B | 1.23B | 2.42B | 2.37B | 249K | 55.0K | 1.81M | 70.2M | 75.5M |
| Total Liabilities | 623M | 1.11B | 1.04B | 2.14B | 2.08B | 54.9K | 27.4K | 26.4K | 10.4M | 11.2M |
| Shareholders' Equity | 43.8M | 20.0M | 194M | 279M | 292M | 195K | 27.7K | 1.78M | 59.9M | 64.3M |
| Cash & Short-term Investments | 109M | 171M | 166M | 317M | 372M | 246K | 7.15K | 49.9K | 19.9K | 20.9K |
| Cash Flow | ||||||||||
| Operating Cash Flow | 51.7M | 12.3M | -42.7M | 86.6M | 125M | -282K | -368K | -259K | -1.28M | -4.32M |
| Capital Expenditure | 11.3M | 23.9M | 53.6M | 62.3M | 94.3M | 0.00 | 0.00 | 0.00 | 2.37K | 17.8K |
| Free Cash Flow | - | - | - | - | - | -282K | -368K | -259K | -1.29M | -4.34M |
| Ratios | ||||||||||
| ROE | - | -115.0% | -46.5% | 2.6% | 16.1% | -147.6% | -30,632.1% | -16.7% | -4.8% | -6.2% |
| ROA | - | -2.0% | -7.3% | 0.3% | 2.0% | -115.1% | -15,397.0% | -16.5% | -4.1% | -5.3% |
| Net Profit Margin | - | -7.1% | -19.0% | 1.3% | 5.5% | - | - | -11,928.1% | -58,026.4% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Nordicus Partners Corporation Common Stock dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | USD 775.00 | 0.00 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2016 | USD 1.10M | - | 2.3% |
| 2015 | USD 100K | - | 1.4% |
| 2014 | USD 15.0M | - | - |
| 2013 | USD 5.00M | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Nov 8, 2024.
Who owns Nordicus Partners Corporation Common Stock
- Insiders 67.02%
- Institutions 0.00%
- Public & others 32.98%
- Shares outstanding 19.4M
- Free float 6.48M
Nordicus Partners Corporation Common Stock company profile
- Company name
- Nordicus Partners Corporation Common Stock
- Ticker
- NORD.US
- Exchange
- USA Stocks
- Listed since
- Mar 26, 2014
- Sector
- Healthcare
- Industry
- Diversified Consumer Services
- Fiscal year end
- August
- Address
- 280 South Beverly Dr, Beverly Hills, CA, United States, 90212
- Phone
- 310 666 0750
- Website
- nordicuspartners.com
About Nordicus Partners Corporation Common Stock
Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California.
Nordicus Partners Corporation Common Stock management
2- Mr. Henrik RoufCEO & President · born 1968
- Mr. Bennett Jay YankowitzCFO & Director · born 1955